In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Biological effects of montelukast, a cysteinyl-leukotriene receptor-antagonist, on T lymphocytes Source: Eur Respir J 2004; 24: Suppl. 48, 129s Year: 2004
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro induction of apoptosis on allergen-specific CD4+ T-cell clones by montelukastSource: Eur Respir J 2001; 18: Suppl. 33, 530s Year: 2001
Suppressive effects of LABAs over the activation of human MDDCs Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation Year: 2010
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Effect of leukotriene receptor antagonist on expression and variation of TGF-beta in T lymphocyte for mild persistent asthma in children Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Effects of PDE4 inhibitors on eotaxin-3 (CCL26) expression in lung epithelial cells Source: Annual Congress 2009 - Epithelial cell biology Year: 2009
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Effects of triptolide on T lymphocyte activation and transcription of interleukin-5 gene and its mechanisms Source: Eur Respir J 2003; 22: Suppl. 45, 483s Year: 2003
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Anti–fibrotic efficacy of Lck inhibitor via the suppression of TGF–ß production in regulatory T cells Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021
Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
The combination of PDE4 and PDE5 inhibitors reduces YAP expression in IPF Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Differing effects of montelukast and ketotifen on cytokine expression in human myeloid dendritic cells Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010